DUBLIN and CHICAGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. FDA approval of a prospective, randomized pivotal clinical trial for the use of Infuse™ Bone Graft ...
A study that disappeared into Medtronic's archives for more than five years contained evidence of potentially deadly problems with the use of the company's Infuse bone-growth product during neck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback